Effectiveness and safety of macrolides in cystic fibrosis patients: A meta-analysis and systematic review

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 5, 2011, Pages 968-978

  Cai, Yun ^a   Chai, Dong ^a   Wang, Rui ^a   Bai, Nan ^a   Liang, Bei Bei ^a   Liu, Youning ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Azithromycin; Clarithromycin; FEV1; FVC; Pseudomonas aeruginosa

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; MACROLIDE; PLACEBO;

ABDOMINAL PAIN; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; COCHRANE LIBRARY; COUGHING; CYSTIC FIBROSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EMBASE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HUMAN; MEDLINE; META ANALYSIS; NAUSEA AND VOMITING; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAMPLE SIZE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CLARITHROMYCIN; CYSTIC FIBROSIS; HUMANS; LUNG; MACROLIDES; PNEUMONIA, BACTERIAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 79954603846     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr040     Document Type: Review

References (33)

1. Becker KA, Grassme H, Zhang Y et al. Ceramide in Pseudomonas aeruginosa infections and cystic fibrosis. Cell Physiol Biochem 2010; 26: 57-66.
2. Ratjen F, Doring G. Cystic fibrosis. Lancet 2003; 361: 681-9.
3. Accurso FJ. Update in cystic fibrosis 2006. Am J Respir Crit Care Med 2007; 175: 754-7.
4. Sibley CD, Rabin H, Surette MG. Cystic fibrosis: a polymicrobial infectious disease. Future Microbiol 2006; 1: 53-61.
5. Flume PA, O'Sullivan BP, Robinson KA et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957-69.
6. Kudoh S, Uetake T, Hagiwara K et al. [Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis]. Nihon Kyobu Shikkan Gakkai Zasshi 1987; 25: 632-42.
7. Dogru D, Dalgic F, Kiper N et al. Long-term clarithromycin in cystic fibrosis: effects on inflammatory markers in BAL and clinical status. Turk J Pediatr 2009; 51: 416-23.
8. Steinkamp G, Schmitt-Grohe S, Doring G et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir Med 2008; 102: 1643-53.
9. Ballard HO, Anstead MI, Shook LA. Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study. Respir Res 2007; 8: 41.
10. Clement A, Tamalet A, Leroux E et al. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 2006; 61: 895-902.
11. Saiman L, Mayer-Hamblett N, Campbell P et al. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 2005; 172: 1008-12.
12. Saiman L, Marshall BC, Mayer-Hamblett N et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749-56.
13. Wolter J, Seeney S, Bell S et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57: 212-6.
14. Florescu DF, Murphy PJ, Kalil AC. Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis. Pulm Pharmacol Ther 2009; 22: 467-72.
15. Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003; 3: CD002203.
16. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
17. Schluchter MD, Konstan MW, Davis PB. Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients. Stat Med 2002; 21: 1271-87.
18. Kerem E, Reisman J, Corey M et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326: 1187-91.
19. Ferrara G, Losi M, Franco F et al. Macrolides in the treatment of asthma and cystic fibrosis. Respir Med 2005; 99: 1-10.
20. McCormack J, Bell S, Senini S et al. Daily versus weekly azithromycin in cystic fibrosis patients. Eur Respir J 2007; 30: 487-95.
21. Kabra SK, Pawaiya R, Lodha R et al. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial. J Cyst Fibros 2010; 9: 17-23.
22. Rotschild M, Elias N, Berkowitz D et al. Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin. Clin Exp Med 2005; 5: 80-5.
23. Equi A, Balfour-Lynn IM, Bush A et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002; 360: 978-84.
24. Saiman L, Anstead M, Mayer-Hamblett N et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010; 303: 1707-15.
25. Altenburg J, de Graaff CS, van der Werf TS et al. Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms. Respiration 2010; 81: 67-74.
26. Garcia-Castillo M, Del Campo R, Baquero F et al. Stationary biofilm growth normalizes mutation frequencies and mutant prevention concentrations in Pseudomonas aeruginosa from cystic fibrosis patients. Clin Microbiol Infect 2010; Epub ahead of print 29 July 2010; doi:10.1111/j.1469-691.2010.03317.x.
27. Tre-Hardy M, Nagant C, El Manssouri N et al. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model. Antimicrob Agents Chemother 2010; 54: 4409-15.
28. Elliott D, Burns JL, Hoffman LR. Exploratory study of the prevalence and clinical significance of tobramycin-mediated biofilm induction in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 2010; 54: 3024-6.
29. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010; 23: 590-615.
30. Wagner VE, Iglewski BH. P. aeruginosa biofilms in CF infection. Clin Rev Allergy Immunol 2008; 35: 124-34.
31. McArdle JR, Talwalkar JS. Macrolides in cystic fibrosis. Clin Chest Med 2007; 28: 347-60.
32. Shinkai M, Rubin BK. Macrolides and airway inflammation in children. Paediatr Respir Rev 2005; 6: 227-35.
33. Lau J, Ioannidis JP, Schmid CH. Summing up evidence: one answer is not always enough. Lancet 1998; 351: 123-7.